Claims for Patent: 8,227,484

Summary for Patent: 8,227,484

Title:	Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
Abstract:	Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
Inventor(s):	Yakatan; Gerald (Del Mar, CA), Berg; James (San Diego, CA), Pope; Laura (Carlsbad, CA), Smith; Richard Alan (La Jolla, CA)
Assignee:	Avanir Pharmaceuticals, Inc. (Aliso Viejo, CA)
Application Number:	13/415,067
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,227,484
Patent Claims:	1. A method for treating pseudobulbar affect or emotional lability, the method comprising administering to a patient in need thereof dextromethorphan in combination with quinidine, wherein the amount of dextromethorphan administered comprises from about 20 mg/day to about 60 mg/day and wherein the amount of quinidine administered comprises from about 10 mg/day to about 30 mg/day with the proviso that the weight-to-weight ratio of dextromethorphan to quinidine is 1:0.75 or less of quinidine. 2. The method of claim 1, wherein the pseudobulbar affect or emotional lability is caused by a neurodegenerative disease or condition or a brain injury. 3. The method of claim 1, wherein the dextromethorphan and the quinidine are administered as one combined dose per day. 4. The method of claim 1, wherein the dextromethorphan and the quinidine are administered as at least two combined doses per day. 5. The method of claim 1, wherein the amount of quinidine administered comprises from about 20 mg/day to 30 mg/day. 6. The method of claim 1, wherein the amount of dextromethorphan administered comprises from about 40 mg/day to 60 mg/day. 7. The method of claim 1, wherein at least one of the quinidine and the dextromethorphan is in a form of a pharmaceutically acceptable salt. 8. The method of claim 1, wherein at least one of the quinidine and the dextromethorphan is in a form of a pharmaceutically acceptable salt selected from the group consisting of salts of free acids, inorganic salts, salts of sulfate, salts of hydrochloride, and salts of hydrobromide. 9. The method of claim 1, wherein about 20 mg quinidine sulfate is administered per day. 10. The method of claim 1, wherein about 60 mg dextromethorphan hydrobromide is administered per day. 11. The method of claim 1, wherein the dextromethorphan and quinidine are administered in separate doses. 12. The method of claim 1, wherein the weight-to-weight ratio of dextromethorphan to quinidine is 1:0.65 or less of quinidine. 13. The method of claim 1, wherein about 40 mg dextromethorphan hydrobromide is administered per day. 14. The method of claim 1, wherein about 60 mg of dextromethorphan and about 20 mg of quinidine is administered per day. 15. The method of claim 1, wherein about 40 mg of dextromethorphan and about 20 mg of quinidine is administered per day. 16. The method of claim 1, wherein about 60 mg of dextromethorphan hydrobromide and about 20 mg of quinidine sulfate is administered per day. 17. The method of claim 1, wherein about 40 mg of dextromethorphan hydrobromide and about 20 mg of quinidine sulfate is administered per day.